Oragenics (Q30291067) is conducting its clinical trials for a concussion treatment, utilizing Southern Star Research as the CRO and David Lloyd as the programme manager.
2 reports, 2 independent
Updated Aug 1
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oragenics (Q30291067) is conducting its clinical trials for a concussion treatment, utilizing Southern Star Research as the CRO and David Lloyd as the programme manager.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Oragenics secured Southern Star Research as CRO and David Lloyd as programme manager for its trials.1 source
James Kelly appointed CMO of Oragenics.1 source
Keep exploring
The entities involved
-
Oragenics (United States)
company in Tampa, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaOragenics partners with Southern Star Research for Phase IIa trial of ONP-002 Oragenics has chosen Australia-based Southern Star Research as the clinical research organisation (CRO) for a randomised
- GlobeNewswireOragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion S